Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Genomics Buys VBC-Biotech Businesses, Establishes Austrian Subsidiary

NEW YORK (GenomeWeb) – Eurofins Genomics today announced the acquisition of VBC-Biotech's oligonucleotide synthesis and DNA sequencing businesses and the establishment of an Austrian subsidiary.

Eurofins Genomics is the genomics division of the Eurofins Scientific Group. The Austrian subsidiary, called Eurofins Genomics AT and headquartered in Vienna, will leverage Eurofins' global network, production capacity, and infrastructure.

"The new direct presence in Austria will provide value to our customers by demonstration our commitment to this market," Eurofins Genomics AT Managing Director Siegfried Schnabl said in a statement. "Furthermore, Vienna will serve as a perfect hub for future business into Central and Eastern Europe and beyond."

Financial and other terms of the deal were not disclosed.

Earlier this month, Eurofins Genomics established a subsidiary in Milan, Italy by buying the oligonucleotide and DNA sequencing business of Primm.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.